Adduct formation in hemoglobin of the newborn mouse exposed in utero to benzo[a]pyrene.
The administration of benzo[a]pyrene topically to pregnant mice during days 13-17 of gestation results in adduct formation in the hemoglobin of the mother and progeny. Thus, exposure to a total maternal body burden of 500 micrograms of benzo[a]pyrene during the last 5 days before delivery resulted in an average level of 6.35 (+/- 0.70 S.E.M.) pg of anti-diolepoxide metabolite covalently attached per mg of hemoglobin analyzed in the mother and 1.40 (+/- 0.23 S.E.M.) in the newborn animals. These data indicate that benzo[a]pyrene administered to the skin of the mother passed across the placental membrane, either as benzo[a]pyrene or some metabolite(s), and was present in the fetal tissue as the "ultimate" carcinogenic form (anti-diolepoxide metabolite) before binding to the hemoglobin. Concomitant adduct formation in the DNA of the skin with benzo[a]pyrene in the progeny was not observed and was probably due to the small amount of carcinogen applied to the mother. The data obtained, along with previously published results [Toxicology, 34 (1985) 211], suggest the suitability of hemoglobin as a molecular dosimeter for estimating carcinogenic risk to polycyclic aromatic hydrocarbons.